These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30353028)

  • 1. Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
    Mohamed AD; Shah N; Hettmer S; Vargesson N; Wackerhage H
    Sci Rep; 2018 Oct; 8(1):15674. PubMed ID: 30353028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
    Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
    J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.
    Tremblay AM; Missiaglia E; Galli GG; Hettmer S; Urcia R; Carrara M; Judson RN; Thway K; Nadal G; Selfe JL; Murray G; Calogero RA; De Bari C; Zammit PS; Delorenzi M; Wagers AJ; Shipley J; Wackerhage H; Camargo FD
    Cancer Cell; 2014 Aug; 26(2):273-87. PubMed ID: 25087979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
    Zhang Z; Du J; Wang S; Shao L; Jin K; Li F; Wei B; Ding W; Fu P; van Dam H; Wang A; Jin J; Ding C; Yang B; Zheng M; Feng XH; Guan KL; Zhang L
    Mol Cell; 2019 Jan; 73(1):7-21.e7. PubMed ID: 30472188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS and YAP1 converge to regulate EMT and tumor survival.
    Shao DD; Xue W; Krall EB; Bhutkar A; Piccioni F; Wang X; Schinzel AC; Sood S; Rosenbluh J; Kim JW; Zwang Y; Roberts TM; Root DE; Jacks T; Hahn WC
    Cell; 2014 Jul; 158(1):171-84. PubMed ID: 24954536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.
    Slemmons KK; Crose LE; Rudzinski E; Bentley RC; Linardic CM
    PLoS One; 2015; 10(10):e0140781. PubMed ID: 26496700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
    Rozengurt E; Eibl G
    World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
    Gruber R; Panayiotou R; Nye E; Spencer-Dene B; Stamp G; Behrens A
    Gastroenterology; 2016 Sep; 151(3):526-39. PubMed ID: 27215660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
    Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
    Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.
    Zhang W; Nandakumar N; Shi Y; Manzano M; Smith A; Graham G; Gupta S; Vietsch EE; Laughlin SZ; Wadhwa M; Chetram M; Joshi M; Wang F; Kallakury B; Toretsky J; Wellstein A; Yi C
    Sci Signal; 2014 May; 7(324):ra42. PubMed ID: 24803537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.
    Slemmons KK; Crose LES; Riedel S; Sushnitha M; Belyea B; Linardic CM
    Mol Cancer Res; 2017 Dec; 15(12):1777-1791. PubMed ID: 28923841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous
    Meder L; Florin A; Ozretić L; Nill M; Koker M; Meemboor S; Radtke F; Diehl L; Ullrich RT; Odenthal M; Büttner R; Heukamp LC
    Pathol Oncol Res; 2021; 27():596522. PubMed ID: 34257546
    [No Abstract]   [Full Text] [Related]  

  • 13. Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.
    Vlahov N; Scrace S; Soto MS; Grawenda AM; Bradley L; Pankova D; Papaspyropoulos A; Yee KS; Buffa F; Goding CR; Timpson P; Sibson N; O'Neill E
    Curr Biol; 2015 Dec; 25(23):3019-34. PubMed ID: 26549256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
    Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
    Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
    Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of human mammary cell tumorigenesis by mutant KRAS requires YAP inactivation.
    Lefort S; Tan S; Balani S; Rafn B; Pellacani D; Hirst M; Sorensen PH; Eaves CJ
    Oncogene; 2020 Feb; 39(9):1957-1968. PubMed ID: 31772328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yap is a novel regulator of C2C12 myogenesis.
    Watt KI; Judson R; Medlow P; Reid K; Kurth TB; Burniston JG; Ratkevicius A; De Bari C; Wackerhage H
    Biochem Biophys Res Commun; 2010 Mar; 393(4):619-24. PubMed ID: 20153295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GNAS
    Ideno N; Yamaguchi H; Ghosh B; Gupta S; Okumura T; Steffen DJ; Fisher CG; Wood LD; Singhi AD; Nakamura M; Gutkind JS; Maitra A
    Gastroenterology; 2018 Nov; 155(5):1593-1607.e12. PubMed ID: 30142336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.